| Trial ID: | L3019 |
| Source ID: | NCT01620463
|
| Associated Drug: |
Liraglutide
|
| Title: |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: Body weight|Vital signs (Blood pressure)|Vital signs (Pulse rate)|ECG (ElectroCardioGram)|Adverse events | Secondary: Area under the plasma NNC 90-1170 curve|Maximum plasma NNC 90-1170 concentration, Cmax|Time to maximum plasma NNC 90-1170 concentration, tmax|Terminal elimination half-life, t1/2|24-hour glucose profile in serum|24-hour insulin profile in serum|24-hour glucagon profile in plasma
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2002-12
|
| Completion Date: |
2003-03
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-24
|
| Locations: |
Novo Nordisk Investigational Site, Tokyo, 1000005, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01620463
|
